4-(1-ethyl-2-methyl-propyl)-morpholine | 67061-39-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 4-(1-ethyl-2-methyl-propyl)-morpholine
• 英文别名: N-(2-methyl-pent-3-yl)-morpholine；4-(2-Methylpentan-3-yl)morpholine
• CAS: 67061-39-6
• 化学式: C₁₀H₂₁NO
• 分子量: 171.283
• InChiKey: NIJVLVVWRRRMMP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Pyridine and Pyrazine derivative for the Treatment of CF
  申请人：BAETTIG Urs

  公开号：US20140135329A1

  公开（公告）日：2014-05-15

  The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.

  本发明提供了吡啶和吡嗪衍生物，可恢复或增强突变和/或野生型CFTR的功能，以治疗囊性纤维化，原发性纤毛运动障碍，慢性支气管炎，慢性阻塞性肺疾病，哮喘，呼吸道感染，肺癌，干燥口腔和角结膜炎，或便秘（IBS，IBD，阿片类药物引起）。还包括含有这些衍生物的药物组合物。
• Pyridine and pyrazine derivative for the treatment of chronic obstructive pulmonary disease
  申请人：Novartis AG

  公开号：EP2845593A1

  公开（公告）日：2015-03-11

  The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat chronic obstructive pulmonary disease. Pharmaceutical compositions comprising such derivatives are also encompassed.

  本发明提供了可恢复或增强突变型和/或野生型 CFTR 功能的吡啶和吡嗪衍生物，用于治疗慢性阻塞性肺病。本发明还包括包含此类衍生物的药物组合物。
• PYRIDINE AND PYRAZINE DERIVATIVE FOR THE TREATMENT OF CF
  申请人：Novartis AG

  公开号：EP2547656B1

  公开（公告）日：2015-09-30
• US8476269B2
  申请人：——

  公开号：US8476269B2

  公开（公告）日：2013-07-02
• [EN] PYRIDINE AND PYRAZINE DERIVATIVE FOR THE TREATMENT OF CF<br/>[FR] DÉRIVÉS DE PYRIDINE ET DE PYRAZINE POUR LE TRAITEMENT DE LA MUCOVISCIDOSE
  申请人：NOVARTIS AG

  公开号：WO2011113894A1

  公开（公告）日：2011-09-22

  The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.

表征谱图